ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor–Induced Thrombotic Microangiopathy
L Erpenbeck, M Demers, ZK Zsengellér… - Journal of the …, 2016 - journals.lww.com
Thrombotic microangiopathy (TMA) is a life-threatening condition that affects some, but not
all, recipients of vascular endothelial growth factor (VEGF) inhibitors given as part of
chemotherapy. TMA is also a complication of preeclampsia, a disease characterized by
excess production of the VEGF-scavenging soluble VEGF receptor 1 (soluble fms-like
tyrosine kinase 1; sFlt-1). Risk factors for VEGF inhibitor–related TMA remain unknown. We
hypothesized that deficiency of the VWF-cleaving ADAMTS13 endopeptidase contributes to …
all, recipients of vascular endothelial growth factor (VEGF) inhibitors given as part of
chemotherapy. TMA is also a complication of preeclampsia, a disease characterized by
excess production of the VEGF-scavenging soluble VEGF receptor 1 (soluble fms-like
tyrosine kinase 1; sFlt-1). Risk factors for VEGF inhibitor–related TMA remain unknown. We
hypothesized that deficiency of the VWF-cleaving ADAMTS13 endopeptidase contributes to …